

ACC Highlights 2024



RECORDED LIVE ON:
MONDAY, APRIL 15, 2024

This program is intended for cardiovascular specialists and primary care physicians from across Canada.



Developed by:



ACC Highlights 2024

FACULTY



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
Assistant Professor, Department of Medicine, University of Toronto
Medical Director, Canadian Collaborative Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA
Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at Augusta University and Mercer University
Atlanta, GA

This program will cover the key clinical trial findings and their implications from ACC 2024. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

- **IMPACT-MI** – Does empagliflozin improve outcomes after acute MI?
- **VICTORION-INITIATE** – Comparing inclisiran first to usual care in patients with ASCVD
- **STEP-HFpEF DM** – What is the role of semaglutide for patients with diabetes and HFpEF?
- **TACT2** – Does chelation reduce events in diabetic post-MI patients?
- **REDUCE-AMI** – Do beta-blockers impact outcome following acute MI with preserved EF?

Learning Objectives:

Following participation in this program, participants will be able to:

- Review trials and data presented at ACC 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice

This program was developed by CCRN and received an unrestricted educational grant from Novartis



Watch the OnDemand recording on CCRN [Here](#)

